About the Journal of Hematology and Oncology Research
Advancing understanding of hematologic and oncologic diseases through rigorous, peer-reviewed research spanning mechanistic, translational, and clinically oriented investigation
The Journal of Hematology and Oncology Research publishes rigorous research that advances understanding of hematologic and oncologic diseases across the continuum of mechanistic, translational, and clinically oriented investigation. While molecular and cellular mechanisms remain core priorities, the journal also welcomes studies that clarify disease progression, identify biomarkers, and link laboratory findings to patient-relevant biological processes.
JHOR considers mechanistic studies, translational analyses using human specimens, observational research with molecular endpoints, biomarker-focused case reports, and clinically grounded investigations that enhance understanding of disease biology. Studies may employ cellular models, patient-derived materials, computational approaches, or clinically collected data, provided they advance biological insight.
The journal serves researchers, clinician-scientists, pathologists, and translational investigators seeking to connect molecular discovery with human disease manifestations. Submissions should clearly describe methodological rigor, biological significance, and contributions to the broader field of hematology and oncology.
Understanding hematologic and oncologic diseases requires investigation at multiple levels — from molecular mechanisms to clinical manifestations. JHOR publishes studies that interrogate disease biology across scales, including genetic and epigenetic alterations, signaling pathway dysregulation, metabolic reprogramming, immune interactions, and clinical correlates. By clarifying disease mechanisms and their clinical implications, we enable the scientific community to identify actionable targets, validate biomarkers, and build models that inform therapeutic strategies.
Our content spans experimental models, patient-derived specimens, computational approaches, observational studies, and integrative analyses. Every manuscript undergoes rigorous peer review to ensure analytical soundness, reproducibility, and biological insight. We welcome studies that challenge existing paradigms, reveal novel disease pathways, refine understanding of complex processes, or document clinically relevant observations with mechanistic depth.
JHOR welcomes investigations across the spectrum of hematologic and oncologic disorders, including both benign hematologic conditions and malignancies. Our editorial priorities reflect the diverse biology of blood diseases and cancer, with an emphasis on rigor and biological significance.
Molecular regulation of blood cell development, stem cell niche interactions, differentiation pathways, and lineage commitment mechanisms.
Anemias, coagulopathies, platelet disorders, hemoglobinopathies, and non-malignant blood cell abnormalities with mechanistic or clinical focus.
Genetic drivers, epigenetic dysregulation, clonal evolution, leukemic stem cell properties, and disease progression biomarkers.
B-cell and T-cell transformation, lymphoid malignancy microenvironments, immune evasion pathways, and molecular subtypes.
Signaling abnormalities, clonal hematopoiesis, mutation landscapes, and disease progression models.
Stromal interactions, immune cell infiltration, angiogenesis, extracellular matrix remodeling, and niche signaling.
Metabolic reprogramming, nutrient dependencies, bioenergetics, redox regulation, and metabolic vulnerabilities in malignancies.
Mutation profiling, chromosomal aberrations, DNA methylation patterns, histone modifications, and non-coding RNA roles.
Kinase cascades, transcription factor networks, growth factor signaling, cell cycle dysregulation, and apoptosis resistance.
Autoimmunity in hematologic conditions, immune checkpoint mechanisms, T-cell exhaustion, and cytokine signaling abnormalities.
Prognostic and predictive markers, liquid biopsy analytes, molecular signatures, and assay development for disease monitoring.
In vitro systems, patient-derived xenografts, organoid cultures, CRISPR-based models, and computational disease simulations.
Molecular pathways conferring therapeutic resistance, compensatory signaling, target mutations, and cellular adaptations.
Observational research with molecular endpoints, biomarker-focused case reports, and clinically grounded investigations linking laboratory findings to disease manifestations.
JHOR requires adherence to established reporting standards to ensure transparency, reproducibility, and methodological rigor across all study types.
Authors submitting observational studies, including cohort, case-control, and cross-sectional designs, must adhere to the STROBE guidelines. These standards ensure clarity in study design, participant selection, variables, data sources, and analytical methods. Submissions must include a completed STROBE checklist uploaded as a supplementary file.
Manuscripts should explicitly address potential sources of bias, confounding, and missing data, and describe steps taken to ensure reproducibility. Studies involving human participants must document ethics approval and consent procedures in accordance with journal requirements.
JHOR requires authors to comply with SAGER guidelines when reporting research involving human participants, tissues, cells, or animals. Manuscripts must specify sex-based inclusion, analytic approaches, and results where applicable. If sex-based analyses are not performed, authors must justify the omission.
All studies must clearly report the sex of biological materials and describe any sex-related limitations in interpretation. These practices enhance rigor and transparency in mechanistic and translational hematology and oncology research.
All manuscripts presenting quantitative data must include detailed statistical methodology sufficient for independent evaluation. Authors must specify statistical tests, assumptions, corrections for multiple comparisons, effect sizes, confidence intervals, and software used. Studies must justify sample sizes and describe handling of missing data.
Submissions lacking adequate statistical rigor may undergo additional statistical assessment or be returned to authors for revision. Reviewers may request raw data to confirm analyses when needed for evaluation.
JHOR operates a single-blind peer review process, with the option for double-blind review upon author request. Each submission is assessed by experts in relevant subdisciplines who evaluate experimental design, analytical methods, data interpretation, reproducibility, and biological insight. Our editorial board, comprising recognized leaders in hematology and oncology research, oversees quality assurance and ensures alignment with the journal's mission.
Methodological Rigor
Reviewers assess study design, controls, statistical approaches, sample size justification, and adherence to reporting standards (ARRIVE, STARD, REMARK, STROBE, SAGER as applicable).
Data Transparency
Authors must disclose data availability, provide supplementary materials, and document reagent sources to enable independent verification and reproducibility.
Ethical Compliance
Studies involving human specimens or animal models require institutional approval documentation, informed consent statements, and adherence to ethical guidelines.
Biological Insight
Manuscripts should emphasize biological understanding, disease mechanisms, biomarker validation, or clinically relevant observations that advance the field.
Authors can submit manuscripts through the Online Manuscript Submission System or via email to [email protected]. Submissions should include a cover letter summarizing the study's contribution, novelty, and alignment with JHOR's scope. Detailed formatting and ethical requirements are outlined in our Instructions for Authors.
Pre-Submission Check
Review JHOR's Aims & Scope to confirm alignment with journal priorities. Ensure ethical approvals are documented and data transparency requirements are met.
Manuscript Preparation
Structure manuscript with clear emphasis on biological insight: background, hypothesis or objectives, methods, results, and interpretation. Include supplementary data and reporting checklists as needed.
Online Submission
Upload manuscript (DOC, DOCX, or PDF), cover letter, figures, supplementary files, and ethics documentation through the submission portal. Receipt is acknowledged within 72 hours.
Peer Review
Manuscripts undergo expert review (typically 2–3 reviewers) assessing biological insight, reproducibility, and analytical rigor. Authors receive decision with reviewer feedback within 3–4 weeks.
Revision & Acceptance
Respond to reviewer comments with point-by-point rebuttal and revised manuscript. Accepted papers proceed to copyediting, author proofing, and online publication (typically within 48 hours of final approval).
JHOR publishes all content under Creative Commons Attribution 4.0 International (CC BY 4.0), ensuring unrestricted access, reuse, and dissemination with proper attribution. Authors retain copyright, enabling inclusion in institutional repositories, grant reports, and derivative works. Article processing charges are levied only upon acceptance; detailed pricing and waiver eligibility are available on the APC information page.
We encourage preprint deposition and support data archiving in recognized repositories (e.g., Gene Expression Omnibus, ArrayExpress, Dryad, Figshare). Clinical trial data should comply with registration and reporting standards; patient-derived data must adhere to privacy regulations and de-identification protocols.
JHOR's archive features studies that have advanced understanding of hematologic and oncologic disease biology. The following articles illustrate the journal's commitment to rigorous, impactful research:
Editorial Board
Led by internationally recognized experts in hematology and oncology research
JHOR's editorial board comprises molecular biologists, clinician-scientists, pathologists, translational researchers, and biomarker specialists with expertise spanning leukemia biology, lymphoma genetics, benign hematologic disorders, solid tumor microenvironments, hematopoietic stem cell regulation, and disease modeling. The editorial team evaluates manuscripts for rigor, analytical soundness, and biological significance, ensuring that published research advances understanding of hematologic and oncologic diseases.
Associate editors oversee subdiscipline-specific pipelines, coordinate peer review, and provide authors with constructive feedback to strengthen clarity and reproducibility. This collaborative editorial model fosters a supportive environment for investigators at all career stages, from early-career researchers to established laboratory leaders.
Advance Understanding of Hematologic and Oncologic Diseases
Join a global community of researchers committed to elucidating the biological basis of blood disorders and malignancies. JHOR provides a rigorous, transparent platform for discoveries that shape the future of hematology and oncology research.
